Zobrazeno 1 - 10
of 201
pro vyhledávání: '"Jean-Claude Bystryn"'
Autor:
Benjamin S. Daniel, Philippe Bernard, Dedee F. Murrell, Michael Hertl, Branka Marinović, Hiroshi Shimizu, José M. Mascaró, Victoria P. Werth, Frédéric Caux, Russell P. Hall, Sergei A. Grando, Jean-Claude Bystryn, Benjamin B. Bince, Aimee S. Payne, David S. Rubenstein, Carlo Pincelli, Daniel Mimouni, John J. Zone, Valeria Aoki, Masayuki Amagai, Janet A. Fairley, Takashi Hashimoto, Pascal Joly, David T. Woodley, Robert A. Swerlick, Giovanna Zambruno, Donna A. Culton, Jasna Lipozenčić, Marcel F. Jonkman, Michael Meurer, David A. Sirois, Enno Schmidt, Giuseppe Cianchini, Detlef Zillikens, Luis A. Diaz, Animesh A. Sinha, Amit G. Pandya, Luca Borradori
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Universidade de São Paulo (USP)
instacron:USP
Our scientific knowledge of bullous pemphigoid (BP) has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials hav
Publikováno v:
Journal of the American Academy of Dermatology. 64:484-489
Background Intravenous immunoglobulin (IVIg)–a relatively new approach to treat pemphigus–lowers serum levels of pemphigus antibodies; however, the optimal way to use this agent is unknown. Objective We sought to examine whether coadministration
Publikováno v:
International Journal of Dermatology. 36:850-854
Autor:
Nico Hunzelmann, Russell P. Hall, A. R. Ahmed, Victoria P. Werth, Amit G. Pandya, Daniel Mimouni, Karen E. Harman, Animesh A. Sinha, Luca Borradori, Maria A. Barnadas, Hiroshi Shimizu, Jean-Claude Bystryn, David S. Rubenstein, Pascal Joly, Neil J. Korman, David P. Fivenson, Masayuki Amagai, Yasuo Kitajima, Giuseppe Cianchini, Linda K. Martin, Marcel F. Jonkman, Sarah Dick, Takashi Hashimoto, Detlef Zillikens, Dedee F. Murrell, David A. Sirois, Pilar Iranzo, Aimee S. Payne, Luis A. Diaz, Michael Hertl
Publikováno v:
Journal of the American Academy of Dermatology, 58(6), 1043-1046. MOSBY-ELSEVIER
Journal of the American Academy of Dermatology; Vol 58
Journal of the American Academy of Dermatology; Vol 58
Our scientific knowledge of pemphigus has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials have helped to de
Publikováno v:
Cancer Immunology, Immunotherapy. 56:1133-1141
Cancer vaccines, while theoretically attractive, present difficult challenges that must be overcome to be effective. Cancer vaccines are often poorly immunogenic and may require augmentation of immunogenicity through the use of adjuvants and/or immun
Autor:
Dean Johnston, Jean-Claude Bystryn
Publikováno v:
Vaccine. 24:1958-1965
A major challenge in the development of more effective vaccines for cancer and other diseases is the development of potent adjuvants that can strongly, simply and safely enhance vaccine immunogenicity. Adjuvants that preferentially enhance Th1 type o
Autor:
Sergei A. Grando, Jean-Claude Bystryn
Publikováno v:
Journal of the American Academy of Dermatology. 54:513-516
Autor:
Diane Jiao, Jean-Claude Bystryn
Publikováno v:
Autoimmunity. 39:601-607
Background: Intraveneous immunoglobulin (IVIg) is increasingly used to treat pemphigus vulgaris (PV). The mechanism by which it does so is not known. The following study was conducted to confirm the effectiveness of IVIg for the acute control of acti
Publikováno v:
Cancer Immunology, Immunotherapy. 55:412-419
A critical element in improving the potency of cancer vaccines, especially pure protein or peptide antigens, is to develop procedures that can strongly but safely increase their ability to induce immune responses. Here, we describe that encapsulation
Publikováno v:
Expert Opinion on Emerging Drugs. 10:393-402
No satisfactory treatment currently exists for melanoma once it has spread beyond its original site. At present, the only FDA-approved treatment for advanced melanoma is IFN-alpha2b. Vaccines are an experimental therapy intended to stimulate the immu